Acute heart failure (AHF) is characterized by the rapid onset or aggravation of symptoms of heart failure. The standard of care in AHF has remained largely unchanged since the 1970s, resulting in a highly genericized market. AHF patients continue to experience high rates of mortality and morbidity because no therapy to date has been able to improve hard clinical outcomes. This study evaluates how current therapies are differentiated based on their performance on key drug attributes and measures the impact of these attributes on the prescribing behavior of cardiologists. Revealing the relative importance of unmet needs helps identify the most attractive opportunities in AHF treatment.

QUESTIONS ANSWERED

  • Which drug attributes most strongly influence AHF drug selection?
  • How do cardiologists rate key current AHF therapies across select drug attributes?
  • Where are the hidden opportunities for drug development in the AHF therapy market?
  • Do U.S. and European cardiologists have different perceptions of the unmet need in the treatment of AHF?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 32 European cardiologists fielded in December 2019.

Key companies: Novartis, Johnson & Johnson, Pfizer.

Key drugs: Nitrate vasodilators, loop diuretics, inotropic sympathomimetics, PDE3 inhibitors, calcium sensitizers.

Table of contents

  • Heart Failure - Unmet Need - Detailed, Expanded Analysis Acute Heart Failure (US/EU)

Author(s): Dwaipayan Chatterjee, M.Pharm

Dwaipayan Chatterjee is an Analyst in the Cardiovascular, Metabolism Renal and Hematology disease team at Decision Resources Group.

He holds a M.Pharm degree with specialization in Pharmaceutical Chemistry from Birla Institute of Technology & Science, Pilani, Rajasthan, India. Prior joining DRG, he worked as an Equity Analyst for the U.S. Healthcare sector with Market Realist working on competitive intelligence and analysis of pharmaceutical financial data. He also worked as a market research analyst for Mordor Intelligence with experience of market sizing, forecasting, and analyzing market dynamics.


Related Reports

Heart Failure - Geographic Focus: China - Heart Failure | China In-Depth | China

Heart failure is a major public health burden in China. With a rapidly rising urban population and a growing trend in unhealthy lifestyles, heart failure is expected to affect a sizable population...

View Details

Heart Failure - Landscape & Forecast - Disease Landscape & Forecast

Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacolog...

View Details

Heart Failure - Current Treatment - Detailed, Expanded Analysis - Chronic Heart Failure - Preserved Ejection Fraction - Treatment Algorithms - Claims Data Analysis - US

Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s pathophys...

View Details

Heart Failure - Current Treatment - Detailed, Expanded Analysis - Chronic Heart Failure - Reduced Ejection Fraction - Treatment Algorithms - Claims Data Analysis - US

Drug treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF)...

View Details